Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968509 | 0.87 | STING1 (0.52) | HINT1HPGDNT5ESTING1PDE3B | |
| SCHEMBL20154882 | 0.87 | STING1 (0.52) | HINT1HPGDNT5ESTING1PDE3B | |
| SCHEMBL19049970 | 0.82 | STING1 (0.42) | HINT1HPGDSTING1GSK3ARPS6KA3 | |
| SCHEMBL19050071 | 0.81 | STING1 (0.41) | HINT1HPGDNT5ESTING1PDE3B | |
| SCHEMBL19050067 | 0.78 | STING1 (0.38) | HINT1HPGDNT5ESTING1 | |
| Guanosine SCHEMBL1030863 | 0.78 | HPGD (0.63) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL19049891 | 0.78 | STING1 (0.52) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL20154870 | 0.78 | HINT1 (0.52) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL19049941 | 0.77 | HINT1 (0.50) | HINT1HPGDNT5ESTING1PDE3B | |
| SCHEMBL24247674 | 0.77 | HINT1 (0.57) | HINT1HPGDNT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | HINT1 620/4885HPGD 2394/4885NT5E 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.